PL3057589T3 - (S)-Pirlindol lub jego farmaceutycznie dopuszczalne sole do zastosowania w medycynie - Google Patents

(S)-Pirlindol lub jego farmaceutycznie dopuszczalne sole do zastosowania w medycynie

Info

Publication number
PL3057589T3
PL3057589T3 PL14726444T PL14726444T PL3057589T3 PL 3057589 T3 PL3057589 T3 PL 3057589T3 PL 14726444 T PL14726444 T PL 14726444T PL 14726444 T PL14726444 T PL 14726444T PL 3057589 T3 PL3057589 T3 PL 3057589T3
Authority
PL
Poland
Prior art keywords
pirlindole
medicine
pharmaceutically acceptable
acceptable salts
salts
Prior art date
Application number
PL14726444T
Other languages
English (en)
Inventor
Filipe Augusto Eugénio Pardal
Pedroso Pedro Filipe Eufrásio
Pecorelli Susana Marques Almeida
Caixado Carlos Alberto Eufrásio Casimiro
Ana Sofia Da Conceição Lopes
João Carlos Damil
Original Assignee
Tecnimede Sociedade Tecnico Medicinal S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Sociedade Tecnico Medicinal S filed Critical Tecnimede Sociedade Tecnico Medicinal S
Publication of PL3057589T3 publication Critical patent/PL3057589T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL14726444T 2014-05-09 2014-05-09 (S)-Pirlindol lub jego farmaceutycznie dopuszczalne sole do zastosowania w medycynie PL3057589T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/PT2014/000029 WO2015171005A1 (en) 2014-05-09 2014-05-09 (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EP14726444.4A EP3057589B1 (en) 2014-05-09 2014-05-09 (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine

Publications (1)

Publication Number Publication Date
PL3057589T3 true PL3057589T3 (pl) 2018-01-31

Family

ID=50819931

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14726444T PL3057589T3 (pl) 2014-05-09 2014-05-09 (S)-Pirlindol lub jego farmaceutycznie dopuszczalne sole do zastosowania w medycynie

Country Status (30)

Country Link
US (1) US9814712B2 (pl)
EP (1) EP3057589B1 (pl)
JP (1) JP6768520B2 (pl)
KR (1) KR102298676B1 (pl)
CN (1) CN106456637B (pl)
AU (1) AU2014393490B2 (pl)
CA (1) CA2948598C (pl)
CY (1) CY1119532T1 (pl)
DK (1) DK3057589T3 (pl)
EC (1) ECSP16086247A (pl)
ES (1) ES2649492T3 (pl)
HR (1) HRP20171651T1 (pl)
HU (1) HUE035071T2 (pl)
IL (1) IL248855B (pl)
LT (1) LT3057589T (pl)
MA (1) MA39447B1 (pl)
MX (1) MX368734B (pl)
NO (1) NO3057589T3 (pl)
NZ (1) NZ726132A (pl)
PH (1) PH12016502233A1 (pl)
PL (1) PL3057589T3 (pl)
PT (1) PT3057589T (pl)
RS (1) RS56591B1 (pl)
RU (1) RU2695647C2 (pl)
SA (1) SA516380264B1 (pl)
SI (1) SI3057589T1 (pl)
SM (1) SMT201700519T1 (pl)
TN (1) TN2016000498A1 (pl)
UA (1) UA118474C2 (pl)
WO (1) WO2015171005A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2988983T3 (es) * 2014-05-09 2024-11-22 Tecnimede Sociedade Tecnico Medicinal S Sales de mandelato de enantiómeros de pirlindol para uso en medicina
SI3054950T1 (sl) 2014-05-09 2017-12-29 Tecnimede-Sociedade Tecnico-Medicinal, S.A. (r)-pirindol in njegove farmacevtsko sprejemljive soli za uporabo v medicini
EP3392250A1 (en) 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Process for the preparation of piperazine ring for the synthesis of pyrazinocarbazole derivatives
EP3392251A1 (en) 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Process for the preparation of pirlindole enantiomers and its salts
MX2018011142A (es) 2018-09-13 2019-10-10 Federico Amezcua Amezcua Combinacion farmaceutica sinergica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona.
EP3900716A1 (en) 2020-04-21 2021-10-27 Dompe' Farmaceutici S.P.A. Co-crystal of gabapentin, ketoprofen and lysine, pharmaceutical compositions and their medical use
CN117717546B (zh) * 2023-10-20 2026-06-12 四川大学华西医院 一种吲哚类衍生物在制备预防和/或治疗疼痛的药物中的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006504795A (ja) * 2002-10-03 2006-02-09 サイプレス バイオサイエンス, インコーポレイテッド 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬
KR20050101537A (ko) * 2002-12-24 2005-10-24 뉴로켐 (인터내셔널) 리미티드 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제
KR20060117909A (ko) * 2003-09-15 2006-11-17 벡투라 리미티드 폐 흡입에 의한 조루 치료용 제약학적 조성물
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
ES2988983T3 (es) * 2014-05-09 2024-11-22 Tecnimede Sociedade Tecnico Medicinal S Sales de mandelato de enantiómeros de pirlindol para uso en medicina

Also Published As

Publication number Publication date
SA516380264B1 (ar) 2019-07-29
NZ726132A (en) 2019-02-22
KR102298676B1 (ko) 2021-09-07
MA39447A1 (fr) 2017-10-31
LT3057589T (lt) 2017-11-27
SI3057589T1 (sl) 2017-12-29
PH12016502233A1 (en) 2017-02-06
DK3057589T3 (da) 2017-11-13
ECSP16086247A (es) 2017-02-24
CN106456637A (zh) 2017-02-22
HUE035071T2 (en) 2018-05-02
IL248855A0 (en) 2017-01-31
AU2014393490A1 (en) 2016-11-24
PT3057589T (pt) 2017-11-29
RU2016148183A3 (pl) 2018-06-13
CA2948598C (en) 2021-06-08
ES2649492T3 (es) 2018-01-12
JP2017518979A (ja) 2017-07-13
TN2016000498A1 (en) 2018-04-04
US20170143709A1 (en) 2017-05-25
RU2016148183A (ru) 2018-06-13
EP3057589A1 (en) 2016-08-24
RS56591B1 (sr) 2018-02-28
NO3057589T3 (pl) 2017-12-30
RU2695647C2 (ru) 2019-07-25
EP3057589B1 (en) 2017-08-02
KR20170002434A (ko) 2017-01-06
AU2014393490B2 (en) 2020-01-02
IL248855B (en) 2020-05-31
CN106456637B (zh) 2020-06-09
MX368734B (es) 2019-10-14
US9814712B2 (en) 2017-11-14
HRP20171651T1 (hr) 2017-12-15
CA2948598A1 (en) 2015-11-12
MA39447B1 (fr) 2018-05-31
SMT201700519T1 (it) 2018-01-11
CY1119532T1 (el) 2018-03-07
MX2016014699A (es) 2017-05-02
UA118474C2 (uk) 2019-01-25
WO2015171005A1 (en) 2015-11-12
JP6768520B2 (ja) 2020-10-14

Similar Documents

Publication Publication Date Title
SI3125883T1 (sl) Indol derivati za uporabo v medicini
IL252532A0 (en) Polycyclic carbamoylpyridone compounds and their pharmaceutical use
IL247072A0 (en) Medical use
PT3277691T (pt) Compostos de carbamoilpiridona policíclicos e sua utilização farmacêutica
IL248855B (en) S-pyralindole and its pharmaceutically acceptable salts for use in medicine
GB2538923B (en) A therapeutic agent for use in the treatment of infections
GB201701400D0 (en) Compound for use in medicine
IL248854A0 (en) R-pyralindole and its pharmaceutically acceptable salts for use in medicine
IL248852A0 (en) Pharmaceutically acceptable salts of pyrilindole enantiomers for use in medicine
GB201406115D0 (en) New pharmaceutical use
GB201616880D0 (en) Compound for use in medicine
GB201409662D0 (en) New pharmaceutical use
TH1601006738A (th) (s)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับ การใช้ในยารักษาโรค
TH1601006737A (th) (r)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับการใช้ ในยารักษาโรค
AP2016009517A0 (en) Indole derivatives for use in medicine
GB201701388D0 (en) Compound for use in medicine
IL251930B (en) Benzylhydroxy derivatives, their preparation and medical uses